0000899243-22-018432.txt : 20220517 0000899243-22-018432.hdr.sgml : 20220517 20220517172709 ACCESSION NUMBER: 0000899243-22-018432 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220515 FILED AS OF DATE: 20220517 DATE AS OF CHANGE: 20220517 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NEUMANN CLARKE CENTRAL INDEX KEY: 0001321466 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39334 FILM NUMBER: 22936012 MAIL ADDRESS: STREET 1: 3595 JOHN HOPKINS CT CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER NAME: FORMER CONFORMED NAME: Neumann Clarke DATE OF NAME CHANGE: 20050323 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIORA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001580063 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 273950390 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4330 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 855-293-2639 MAIL ADDRESS: STREET 1: 4330 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: PROGENITY, INC. DATE OF NAME CHANGE: 20150617 FORMER COMPANY: FORMER CONFORMED NAME: ASCENDANT MDX, INC. DATE OF NAME CHANGE: 20130625 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-05-15 0 0001580063 BIORA THERAPEUTICS, INC. BIOR 0001321466 NEUMANN CLARKE C/O BIORA THERAPEUTICS, INC. 4330 LA JOLLA VILLAGE DRIVE, SUITE 300 SAN DIEGO CA 92122 0 1 0 0 See Remarks Common Stock 2022-05-15 4 F 0 8305 0.75 D 308320 D Common Stock 2022-05-15 4 A 0 239962 0.00 A 548282 D Stock Option (Right to Buy) 0.75 2022-05-15 4 A 0 387752 0.00 A 2032-05-15 Common Stock 387752 387752 D Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of 24,014 vested restricted stock units on May 15, 2022. Consists of 239,962 restricted stock units, 25% of which will vest on May 15, 2023, with the remaining shares vesting in equal semi-annual installments through May 15, 2026, subject to the Reporting Person's continued service to the Issuer. This option represents the right to purchase 387,752 shares of the Issuer's common stock, 8,078 of which vested upon grant, with the remaining shares vesting in equal monthly installments through April 15, 2026, subject to the Reporting Person's continued service to the Issuer. Senior Vice President, General Counsel and Secretary /s/ Will Pridgen, Attorney-in-Fact for Clarke Neumann 2022-05-17